TrialTransplantation and cellular therapy2022

Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients.

Rebecca Epperly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.